<DOC>
	<DOCNO>NCT00747526</DOCNO>
	<brief_summary>The purpose study evaluate pharmacokinetics ( drug absorb body , distribute within body remove body time ) , pharmacodynamics ( study medication affect body ) safety rabeprazole single multiple daily administration infant age 1 11 month , inclusive , Gastroesophageal Reflux Disease ( GERD ) .</brief_summary>
	<brief_title>A Study Single Multiple Doses Rabeprazole Pediatric Patients With Gastroesophageal Reflux Disease ( GERD ) 1 11 Months Old , Inclusive</brief_title>
	<detailed_description>This open-label ( physician patient know name study medication ) , multicenter , Phase I study , consist 2 part . The first part study nonrandomized ( study drug intentionally assign ) , patient receive dose . In second part study , patient randomize ( study medication assign chance ) 2 dose group . The purpose study evaluate pharmacokinetics ( PK ) , pharmacodynamics ( intraesophageal/intragastric pH , clinical global impression , formulation palatability Gastroesophageal Reflux Disease ( GERD ) daily symptom diary ) safety rabeprazole single multiple daily administration 2 dose level child age 1 11 month , inclusive ( 11 month 29 day ) , GERD . As study exploratory assessment PK , pharmacodynamics safety rabeprazole child , formal hypothesis test apply . Safety tolerability , include monitor adverse event , clinical laboratory result , physical examination , vital sign electrocardiogram measurement ( measure electrical current heart ) , evaluate throughout study . Patients receive rabeprazole sodium single daily oral dos 5 successive day ( Option 1 ) , 14 successive day ( 10 day minimum ) ( Option 2 ) bead formulation . In Part 1 , patient receive single multiple daily ( every 24 hour ) dose 0.5 mg/kg , use increment 1 mg dose . Safety PK data Part 1 study determine 2 dosage study Part 2 study . In Part 2 , patient may receive rabeprazole sodium single daily oral dos maximum 28 consecutive day bead formulation . Patients randomize either 5 mg dose 10 mg dose group .</detailed_description>
	<mesh_term>Gastroesophageal Reflux</mesh_term>
	<mesh_term>Rabeprazole</mesh_term>
	<criteria>Minimum weight 5 kg ( treatment Option 1 ) 3 kg ( treatment Option 2 ) diagnosis GERD Informed consent sign least one parent Patients treat , currently receive proton pump inhibitor ( PPI ) , H2 blocker , antacid eligible ( long go antacids 24 hour , PPIs H2 blocker three day prior dose , except cimetidine , must discontinue least seven day prior dose ) remain medication treatment period Patients history current clinically significant medical illness ( exclude GERD ) include ( limited ) cardiac arrhythmia cardiac disease , hematologic disease , coagulation disorder ( include abnormal bleeding blood dyscrasia ) , lipid abnormality , diabetes mellitus , renal hepatic insufficiency , thyroid disease , infection , illness investigator considers exclude patient could interfere interpretation study result Primary pulmonary ear , nose , throat ( ENT ) symptoms History current presence peptic ulcer Presence `` warning signal '' , suggest cause vomiting/regurgitation GERD Any condition would make patient , opinion Investigator Sponsor , unsuitable study</criteria>
	<gender>All</gender>
	<minimum_age>1 Month</minimum_age>
	<maximum_age>11 Months</maximum_age>
	<verification_date>July 2013</verification_date>
	<keyword>Gastroesophageal Reflux Disease ( GERD )</keyword>
	<keyword>Pediatrics</keyword>
	<keyword>Pharmacokinetics</keyword>
	<keyword>Pharmacodynamics</keyword>
	<keyword>Rabeprazole</keyword>
	<keyword>GERD</keyword>
	<keyword>Aciphex</keyword>
</DOC>